




Antibiotice



CURRENT REPORT

Reporting date: **01.12.2021**

Name of the issuing entity: **Antibiotice SA**

Registered office: **lași, str. Valea Lupului nr.1, cod poștal 707410,**

<http://www.antibiotice.ro>

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Phone/fax number: **+40232 209000 / 0372 065 633**

Sole Registration Code with the Trade Register Office: **RO1973096**

Order number in the Trade Register Office: **J22/285/1991**

Subscribed and paid share capital: **67.133.804 lei**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange**

Number of shares: **671.338.040**

Number of votes: **671.338.040**

The main characteristics of the securities issued by the trading company: **registered shares, nominal value: 0.10 lei**

Important event to be reported:

Antibiotice wins tender worth 11 million euros in the UK

Antibiotice Iasi won the tender held by the UK Department of Health and Social Care for a number of 5 anti-infective products for injection.

Antibiotice won the tender launched by the UK authorities for five injectable anti-infectives (for hospital use), which are used in the treatment of Covid-19 associated bacterial superinfections as well.

“We are glad that today, on December 1, Antibiotice - a Romanian brand with 65 years of history - can make this achievement known. It is a further proof that high level of performance can be attained in our country as well, that Romania has a future!

The value of the recently concluded contract amounts to EUR 11 million, which not only allows the future consolidation of the business, but also reconfirms our status of medicinal product manufacturer accepted by one of the largest regulated markets in Western Europe”, said Ioan Nani, the CEO of Antibiotice.

The contract will run for a period of 2 years, and the first deliveries will be made starting January 2022, without jeopardizing the supply of all hospitals in Romania with beta-lactam medicinal products for injection.

Entering the UK market is part of the territorial expansion strategy of Antibiotice, which is included in the company's long-term Strategic Organization and Development Plan. Moreover, aiming at enhancing its portfolio in the coming years by adding products adapted to the today's therapeutics, Antibiotice carries out different projects in Brazil, Australia and Northern Europe countries (Finland, Sweden, Norway, Denmark). Such projects will increase the presence of the company in these markets and generate significant sales.

In recent years, Antibiotice has won important tenders for anti-infective medicines in the US, Western Europe, Southeast Asia, as well as the tender launched by the European Committee in 2020, intended to ensure the appropriate supply with beta-lactam antibiotics of the member states during the pandemics. This represents a true acknowledgement of the quality of the medicinal products manufactured by Antibiotice at Iași, in Romania.

General Director,

Ec. Ioan NANI

